Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 28 of 28 results for osimertinib

  1. Treatment for lung cancer

    The section of the NICE impact lung cancer report looking at how the disease is treated.

  2. Past appeals and decisions

    treating Niemann-Pick disease types A and B 24 May 2024 TA621 Osimertinib for untreated EGFR-positive non-small-cell lung cancer 30...

  3. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2022
    View recommendations

    Sections for TA823

  4. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA584

  5. Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

    Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA898

  6. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1017

  7. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Technology appraisal guidance
    Published
    22 January 2020

  9. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    15 January 2025

    Sections for TA1030

  10. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Technology appraisal guidance
    Published
    26 October 2016

  11. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Technology appraisal guidance
    Published
    19 January 2022

  12. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  13. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.

    News
    Last updated
    21 January 2025